| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30b4afcf7da0adf2046b591d2740ae87 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-904
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0698
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0629
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2015-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c837df3d2f37b06d7bf3642e6e4bfa67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275832ac817a5788ff828e0a7fe6be7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb7303ad50469c32fbd30e36f3e8fa22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4eade72024ca442f72acf3d6ec1a38a5 |
| publicationDate |
2016-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3092303-A1 |
| titleOfInvention |
Reconstituted nipple skin model |
| abstract |
A first subject of the invention is a skin model characterized in that it comprises keratinocytes capable of overexpressing filaggrin. A second subject of the invention is a method for evaluating the in vitro activity of a formulation or of at least one active agent on the healing of nipple skin and/or on the reduction of nipple skin inflammation, characterized in that said method comprises at least the following steps: a) bringing said active agent or said formulation into contact with a skin model comprising keratinocytes overexpressing filaggrin and also comprising a lesion; b) measuring the level of production of at least one biological marker in the nipple skin model of step a), characterized in that said biological marker can be chosen from lactate dehydrogenase (LDH), TNFα, filaggrin, TGFβ1 and β1 integrin; c) comparing the level of production of at least one biological marker obtained in step b) with a reference level of production; evaluating the efficacy of said active agent or of said formulation according to the comparison of step c). |
| priorityDate |
2014-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |